Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Allogene Therapeutics (ALLO)

Allogene Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALLO
DateTimeSourceHeadlineSymbolCompany
26/04/202413:30GlobeNewswire Inc.Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell CarcinomaNASDAQ:ALLOAllogene Therapeutics Inc
09/04/202413:30GlobeNewswire Inc.Allogene Therapeutics Announces Q2 Investor Conference ParticipationNASDAQ:ALLOAllogene Therapeutics Inc
14/03/202420:05GlobeNewswire Inc.Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
12/03/202412:30GlobeNewswire Inc.Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune DiseaseNASDAQ:ALLOAllogene Therapeutics Inc
05/03/202413:30GlobeNewswire Inc.Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
28/02/202413:30GlobeNewswire Inc.Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
16/02/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLOAllogene Therapeutics Inc
16/02/202413:30GlobeNewswire Inc.Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in AsiaNASDAQ:ALLOAllogene Therapeutics Inc
31/01/202422:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
24/01/202422:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
22/01/202421:11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
16/01/202421:05GlobeNewswire Inc.Allogene Therapeutics Announces Participation in Upcoming Investor ConferencesNASDAQ:ALLOAllogene Therapeutics Inc
05/01/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLOAllogene Therapeutics Inc
04/01/202421:15GlobeNewswire Inc.Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell LymphomaNASDAQ:ALLOAllogene Therapeutics Inc
04/01/202421:05GlobeNewswire Inc.Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell LymphomaNASDAQ:ALLOAllogene Therapeutics Inc
03/01/202421:05GlobeNewswire Inc.Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
20/12/202321:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
19/12/202320:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLOAllogene Therapeutics Inc
18/12/202321:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
09/12/202317:00GlobeNewswire Inc.Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of HematologyNASDAQ:ALLOAllogene Therapeutics Inc
01/12/202313:30GlobeNewswire Inc.Allogene Therapeutics Announces Participation in December Investor ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
03/11/202316:00GlobeNewswire Inc.Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual MeetingNASDAQ:ALLOAllogene Therapeutics Inc
03/11/202316:00GlobeNewswire Inc.Allogene Therapeutics Presents Preclinical Data on Next Generation Cloakâ„¢ and Daggerâ„¢ Technologies at the Society for Immunotherapy of Cancer Annual MeetingNASDAQ:ALLOAllogene Therapeutics Inc
02/11/202320:41Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLOAllogene Therapeutics Inc
02/11/202320:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLOAllogene Therapeutics Inc
02/11/202320:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLOAllogene Therapeutics Inc
02/11/202320:02GlobeNewswire Inc.Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
02/11/202313:00GlobeNewswire Inc.Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of HematologyNASDAQ:ALLOAllogene Therapeutics Inc
30/10/202312:30GlobeNewswire Inc.Allogene Therapeutics Announces Participation in November Investor ConferencesNASDAQ:ALLOAllogene Therapeutics Inc
26/10/202313:30GlobeNewswire Inc.Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023NASDAQ:ALLOAllogene Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALLO